**Supplementary file 1.** Model glossary / parameter table.

|  |  |  |
| --- | --- | --- |
| **Symbol†** | **Description** | **Comments** |
| *a* | Trial arm | Coded 0 = control arm; 1 = vaccine arm  |
| *b* | Baseline serostatus | Coded 0 = seronegative; 1 = seropositive |
| *c* | Country |  |
| *d* | Dengue serotype |  |
| *D* | Disease/case type | Coded 0 = active phase; 1 = passive phase by defaultCoded 0 = non-hospitalised; 1 = hospitalised if considering hospitalisationCoded 0 = non-severe; 1 = severe if considering severe disease |
| *α* | Age | Age group 1 = 2-5 years; Age group 2 = 6-11 years; Age group 3 = 12-16 years  |
| *t* | Calendar time | Units in days |
| *t\** | Time post dose | Units in days |
| *tF* | Time of most recent dose |  |
| *λabcdD(t, α)* | Hazard in trial arm *a* for baseline serostatus *b* in country *c* from serotype *d* of disease type *D* at calendar time *t* at age *α* |  |
| *λc(t)* | Baseline hazard in country *c* at time *t* | Assumed to be constant over interval *TI =* 1 day. Each country modelled as quadratic spline where knots *κck* are fitted parameters  |
| ***Mb*** | Multiplier of baseline hazard for serostatus *b* | Reflects seropositives reduced susceptibility to infection (not disease) due to their previous infection with and immunity to at least one serotype. Fitted with prior *Unif*(0,1). Fixed at 1 for seronegatives. |
| *ρcd* | Proportion of serotype *d* in country *c* | Assumed constant over observation period |
| ***qcy*** | Parameters governing serotype proportions *ρcd*in each country *c* (see Methods) | Fitted with prior *Unif*(0,1) |
| ***Z(α)*** | Age specific multiplier of baseline hazard | Piecewise constant step function for age groups 1 (2-5yrs), 2 (6-11yrs) and 3 (12-16 yrs). Value for age group 1 fixed at 1 (baseline). Constant values are fitted parameters with prior *Unif*(0,5). |
| ***Ki,D*** | Relative risk of disease of type *D* given *i* previous infections. *K1,0* := 1 taken as baseline. Risks from tertiary and quaternary infections assumed to be equal, i.e. *K2D = K3D*. | *K0,0* and *K2,0* fitted with prior *Unif*(0,1). *K1,1* fitted with prior *Unif*(0,0.5). We fix the ratios *K0,1 / K1,1* = *K2,1 / K1,1* = 0.25 (as in [10])  |
| *φcD(α)* | Seropositive disease risk where number of previous infections unknown | Weighted average of seropositive (monotypic and multitypic) relative risks of disease type *D* given participants age *α* and country *c* |
| *RabcD(α)* | Relative risk of disease of type *D* in stratum *a, b, c.* | Term wrapper of: i) seronegative (*K0,D*) and seropositive (*φcD(α)*) disease risk; ii) change in long term disease risk from “silent infection” vaccination |
| *δa,Vac* | Kronecker delta | 0 if subject in control arm, 1 if subject in vaccine arm |
| ***τb*** | Mean duration of transient immunity for serostatus *b* | Fitted with prior *Unif*(0,10) for *b = 0* (seronegatives) and *Unif*(0,20) for *b = 1* (seropositives)  |
| *Ibd(α)* | Initial transient immunity for baseline serostatus *b*, serotype *d* at age *α* | Sum of *Ab(α)* and *sbd*below. Prior is *Unif*(-10,1) for *b = 0* (seronegatives) and *Unif*(0,1) for *b = 1* (seropositives) |
| ***Ab(α)*** | Transient immunity with age for serostatus *b* | Piecewise constant step function for age groups 1 (2-5yrs), 2 (6-11yrs) and 3 (12-16 yrs). Constant values are fitted parameters with prior *Unif*(-10,1) for *b = 0* (seronegatives) and *Unif*(0,1) for *b = 1* (seropositives) |
| ***sbd*** | Intercept of transient immunity for baseline serostatus *b* and serotype *d* | Fixed at 0 for serotype *d* = 1, otherwise fitted with prior *Unif*(-10,1) for *b = 0* (seronegatives) and *Unif*(0,1) for *b = 1* (seropositives) |
| *I\*bd(α,t,tF)* | transient immunity remaining at time *t* after most recent dose *tF* against serotype *d* for baseline serostatus *b* for age *α*  |  |
| ***hc*** | Historical hazard of infection in country *c.* | Fitted with prior *Unif*(0,1) |
| ***κck*** | *k*’th knot of spline in country *c* | Knots spaced at 1/3-year (approx. 4-month) intervals between 3rd Oct 2011 and 31st Jan 2015 . Knots explicitly determine values of *λc(t)*. Logged knots are fitted parameters with prior *Unif*(-6,0) |
| *βick* | Coefficient of *ith* power of *kth* polynomial of baseline hazard spline in country *c* |  |
| *p0c(α), p1c(α)* | Probabilities of exactly 0 and 1 prior infections by age *α* in country *c* |  |
| *λabcD(t, α)* | Hazard from any serotype | Sum of *λabcdD(t, α)* over all serotypes *d* |
| *λ\*abc(t, α)* | Hazard from any serotype in either trial phase | Wrapper of *λabcD(t, α)* |
| *Λabc(tS,tE,α)* | Integrated hazard between *tS* and *tE* |  |
|  | Probability of remaining disease-free between *tS* and *tE* |  |
|  | Probability or remaining disease-free between *tS* and *tE* and contracting disease of type *D* from serotype *d* at time *tF* |  |
|  | Probability of clinical outcome *C.* |  |
| *πbc(α)* | Probability of serostatus *b* in country *c* at age *α* |  |
| *L(θ)* | Likelihood of parameter set *θ* |  |
| *HRS(t\*)* | Hazard ratio (vaccine:control) in stratum *S* due to any serotype or disease/case type after *t\** days post first dose |  |
| *HRS(t\*,d,D)* | Hazard ratio (vaccine:control) of disease type *D* in stratum *S* due to serotype *d* after *t\** days post first dose |  |
|  | Probability of remaining disease-free *t\** days post first dose, aggregated across stratum *S*  |  |
| *AR(Trial Period)* | Attack rate over trial period (either active phase or passive phase) |  |

† Symbols in bold font refer to fitted parameters.